A detailed history of Van Cleef Asset Management,Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Van Cleef Asset Management,Inc holds 7,705 shares of ABBV stock, worth $1.37 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
7,705
Previous 7,705 -0.0%
Holding current value
$1.37 Million
Previous $1.32 Million 15.14%
% of portfolio
0.17%
Previous 0.17%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$159.82 - $182.1 $7,991 - $9,105
-50 Reduced 0.64%
7,705 $1.4 Million
Q4 2023

Feb 02, 2024

BUY
$137.6 - $154.97 $13,760 - $15,497
100 Added 1.31%
7,755 $1.2 Million
Q3 2023

Nov 07, 2023

SELL
$133.59 - $154.65 $3,339 - $3,866
-25 Reduced 0.33%
7,655 $1.14 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $212,016 - $263,840
-1,600 Reduced 17.24%
7,680 $1.03 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $5,784 - $6,661
-40 Reduced 0.43%
9,280 $1.48 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $27,662 - $33,174
200 Added 2.19%
9,320 $1.51 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $41,605 - $47,718
-310 Reduced 3.29%
9,120 $1.22 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $27,931 - $35,341
-260 Reduced 2.68%
9,430 $1.28 Million
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $7,980 - $9,058
-75 Reduced 0.77%
9,690 $1.05 Million
Q2 2021

Aug 16, 2021

SELL
$105.21 - $117.21 $15,781 - $17,581
-150 Reduced 1.51%
9,765 $1.1 Million
Q1 2021

May 17, 2021

SELL
$102.3 - $112.62 $20,460 - $22,524
-200 Reduced 1.98%
9,915 $1.07 Million
Q4 2020

Feb 17, 2021

SELL
$80.49 - $108.67 $8,048 - $10,867
-100 Reduced 0.98%
10,115 $1.08 Million
Q3 2020

Nov 16, 2020

SELL
$85.91 - $100.83 $90,205 - $105,871
-1,050 Reduced 9.32%
10,215 $895,000
Q2 2020

Aug 17, 2020

BUY
$73.37 - $98.18 $66,033 - $88,362
900 Added 8.68%
11,265 $1.11 Million
Q1 2020

May 15, 2020

SELL
$64.5 - $97.79 $126,420 - $191,668
-1,960 Reduced 15.9%
10,365 $790,000
Q4 2019

Feb 14, 2020

SELL
$72.13 - $90.25 $14,426 - $18,050
-200 Reduced 1.6%
12,325 $1.09 Million
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $3,274 - $3,937
-52 Reduced 0.41%
12,525 $948,000
Q2 2019

Aug 13, 2019

BUY
$65.7 - $83.98 $32,915 - $42,073
501 Added 4.15%
12,577 $915,000
Q1 2019

May 13, 2019

BUY
$77.14 - $90.79 $27,770 - $32,684
360 Added 3.07%
12,076 $973,000
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $23,043 - $28,418
296 Added 2.59%
11,716 $1.08 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $54,679 - $60,786
-615 Reduced 5.11%
11,420 $1.08 Million
Q2 2018

Aug 10, 2018

BUY
$89.78 - $106.23 $14,364 - $16,996
160 Added 1.35%
12,035 $1.12 Million
Q1 2018

May 04, 2018

SELL
$92.01 - $123.21 $10,581 - $14,169
-115 Reduced 0.96%
11,875 $1.12 Million
Q4 2017

Feb 02, 2018

SELL
$89.56 - $98.21 $11,195 - $12,276
-125 Reduced 1.03%
11,990 $1.16 Million
Q3 2017

Oct 27, 2017

BUY
$69.85 - $89.22 $846,232 - $1.08 Million
12,115
12,115 $1.08 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $315B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Van Cleef Asset Management,Inc Portfolio

Follow Van Cleef Asset Management,Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Cleef Asset Management,Inc, based on Form 13F filings with the SEC.

News

Stay updated on Van Cleef Asset Management,Inc with notifications on news.